Misba Beerahee

521 total citations
34 papers, 405 citations indexed

About

Misba Beerahee is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Misba Beerahee has authored 34 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Physiology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Misba Beerahee's work include Asthma and respiratory diseases (16 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (12 papers) and Inhalation and Respiratory Drug Delivery (7 papers). Misba Beerahee is often cited by papers focused on Asthma and respiratory diseases (16 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (12 papers) and Inhalation and Respiratory Drug Delivery (7 papers). Misba Beerahee collaborates with scholars based in United Kingdom, United States and Sweden. Misba Beerahee's co-authors include Deborah A. Smith, Elisabeth A. Minthorn, Shuying Yang, Rashmi Mehta, Alison Church, Jean Brooks, Navin Goyal, Sally Kilbride, Chris Kalberg and Anthony Cahn and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and Thorax.

In The Last Decade

Misba Beerahee

34 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Misba Beerahee United Kingdom 12 209 164 72 65 34 34 405
Monika Malm-Erjefält Sweden 10 159 0.8× 59 0.4× 114 1.6× 108 1.7× 31 0.9× 10 403
Liting Zhang China 12 83 0.4× 80 0.5× 23 0.3× 81 1.2× 28 0.8× 47 326
Wiebke Janssen Germany 13 82 0.4× 395 2.4× 55 0.8× 147 2.3× 29 0.9× 35 629
Guanming Qi China 11 45 0.2× 91 0.6× 67 0.9× 112 1.7× 31 0.9× 23 460
Yijun Dong China 10 43 0.2× 34 0.2× 33 0.5× 103 1.6× 35 1.0× 35 325
Ha Nguyen United States 9 417 2.0× 364 2.2× 31 0.4× 67 1.0× 27 0.8× 12 735
Jean-Claude Dussaule France 9 59 0.3× 98 0.6× 27 0.4× 119 1.8× 10 0.3× 9 348
Wojciech Barg Poland 12 95 0.5× 91 0.6× 29 0.4× 107 1.6× 14 0.4× 40 438
Esther Barrionuevo Spain 15 293 1.4× 67 0.4× 76 1.1× 26 0.4× 4 0.1× 27 607
Kailong Li China 10 90 0.4× 58 0.4× 50 0.7× 183 2.8× 22 0.6× 32 586

Countries citing papers authored by Misba Beerahee

Since Specialization
Citations

This map shows the geographic impact of Misba Beerahee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Misba Beerahee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Misba Beerahee more than expected).

Fields of papers citing papers by Misba Beerahee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Misba Beerahee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Misba Beerahee. The network helps show where Misba Beerahee may publish in the future.

Co-authorship network of co-authors of Misba Beerahee

This figure shows the co-authorship network connecting the top 25 collaborators of Misba Beerahee. A scholar is included among the top collaborators of Misba Beerahee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Misba Beerahee. Misba Beerahee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ambery, Claire, et al.. (2023). Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials. Journal of Pharmacokinetics and Pharmacodynamics. 50(4). 297–314. 3 indexed citations
2.
Begg, Malcolm, Augustin Amour, Teresa Tang, et al.. (2023). An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome. Pulmonary Pharmacology & Therapeutics. 79. 102201–102201. 13 indexed citations
3.
Mohan, Divya, Harry B. Rossiter, Henrik Watz, et al.. (2022). Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial. Thorax. 78(3). 258–266. 19 indexed citations
4.
5.
Farrell, Colm, et al.. (2022). Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data. The Journal of Clinical Pharmacology. 63(5). 593–603. 1 indexed citations
6.
Ludbrook, Valerie J., James L. Kreindler, Joanna Marks-Kończalik, et al.. (2021). Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough. ERJ Open Research. 7(3). 269–2021. 21 indexed citations
7.
Ambery, Claire, Shuying Yang, Maggie Tabberer, et al.. (2021). Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial. The AAPS Journal. 23(4). 79–79. 3 indexed citations
8.
Beerahee, Misba, David J. Behm, Philipp Badorrek, et al.. (2020). Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge. Pulmonary Pharmacology & Therapeutics. 64. 101977–101977. 13 indexed citations
9.
Germovsek, Eva, Claire Ambery, Shuying Yang, et al.. (2019). A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients. The AAPS Journal. 21(4). 60–60. 3 indexed citations
10.
Beerahee, Misba, et al.. (2019). Bayesian approach to investigate a two-statemixed model of COPD exacerbations. Journal of Pharmacokinetics and Pharmacodynamics. 46(4). 371–384. 1 indexed citations
11.
Mehta, Rashmi, Misba Beerahee, Noushin Brealey, et al.. (2018). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. The Journal of Clinical Pharmacology. 58(11). 1461–1467. 3 indexed citations
12.
Church, Alison, et al.. (2014). Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulmonary Medicine. 14(1). 2–2. 27 indexed citations
13.
Russu, Alberto, et al.. (2014). Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response. Journal of Pharmacokinetics and Pharmacodynamics. 41(6). 553–569. 5 indexed citations
14.
Mosteller, Michael, et al.. (2014). Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor. Pharmacogenetics and Genomics. 24(12). 618–621. 5 indexed citations
15.
Donohue, James F., Christopher Kalberg, Misba Beerahee, et al.. (2014). Dose response of umeclidinium administered once or twice daily in patients with COPD: A pooled analysis of two randomized, double‐blind, placebo‐controlled studies. The Journal of Clinical Pharmacology. 54(11). 1214–1220. 14 indexed citations
16.
Yang, Shuying, et al.. (2012). Population Pharmacokinetics of Losmapimod in Healthy Subjects and Patients with Rheumatoid Arthritis and Chronic Obstructive Pulmonary Diseases. Clinical Pharmacokinetics. 52(3). 187–198. 11 indexed citations
17.
Smith, Deborah A., Elisabeth A. Minthorn, & Misba Beerahee. (2011). Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody. Clinical Pharmacokinetics. 50(4). 215–227. 76 indexed citations
18.
Yang, Shuying & Misba Beerahee. (2010). Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug–drug interaction studies. European Journal of Clinical Pharmacology. 67(3). 225–233. 11 indexed citations
19.
Hussein, Ziad, Misba Beerahee, R. F. Grover, et al.. (1999). Pharmacokinetics of the nitric oxide synthase inhibitor --methylarginine hydrochloride in patients with septic shock. Clinical Pharmacology & Therapeutics. 65(1). 1–9. 19 indexed citations
20.
Beerahee, Misba. (1999). Clinical Pharmacology of Atovaquone and Proguanil Hydrochloride. Journal of Travel Medicine. 6(S1). S13–S20. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monika Malm-Erjefält Breakdown of academic impact, for papers by Liting Zhang Breakdown of academic impact, for papers by Wiebke Janssen Breakdown of academic impact, for papers by Guanming Qi Breakdown of academic impact, for papers by Yijun Dong Breakdown of academic impact, for papers by Ha Nguyen Breakdown of academic impact, for papers by Jean-Claude Dussaule Breakdown of academic impact, for papers by Wojciech Barg Breakdown of academic impact, for papers by Esther Barrionuevo Breakdown of academic impact, for papers by Kailong Li
Rankless by CCL
2026